COVID-19 vaccination challenges: A mini-review
The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end th...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2066425 |
| _version_ | 1797673211589033984 |
|---|---|
| author | Zeinab Mohseni Afshar Mohammad Barary Rezvan Hosseinzadeh Bardia Karim Soheil Ebrahimpour Kosar Nazary Terence T. Sio Mark J. M. Sullman Kristin Carson-Chahhoud Emaduddin Moudi Arefeh Babazadeh |
| author_facet | Zeinab Mohseni Afshar Mohammad Barary Rezvan Hosseinzadeh Bardia Karim Soheil Ebrahimpour Kosar Nazary Terence T. Sio Mark J. M. Sullman Kristin Carson-Chahhoud Emaduddin Moudi Arefeh Babazadeh |
| author_sort | Zeinab Mohseni Afshar |
| collection | DOAJ |
| description | The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end the pandemic. At the beginning of the program, vaccinations were initially targeted only at high-risk groups, such as the elderly, those with comorbidities, or healthcare workers. Although most of the mentioned populations have received the two recommended doses, limited resources have left many authorities with an effective vaccine undersupply. Therefore, policies have been implemented to manage the available doses of the vaccines more efficiently. As there is no universally agreed consensus on this topic, we discuss the different recommendations and guidelines regarding the time interval between the two vaccine doses and explain the different scenarios for applying the two doses. |
| first_indexed | 2024-03-11T21:41:09Z |
| format | Article |
| id | doaj.art-e241dd7d1e4b4f4f8a6add435ac61f5d |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:41:09Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-e241dd7d1e4b4f4f8a6add435ac61f5d2023-09-26T13:19:06ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118510.1080/21645515.2022.20664252066425COVID-19 vaccination challenges: A mini-reviewZeinab Mohseni Afshar0Mohammad Barary1Rezvan Hosseinzadeh2Bardia Karim3Soheil Ebrahimpour4Kosar Nazary5Terence T. Sio6Mark J. M. Sullman7Kristin Carson-Chahhoud8Emaduddin Moudi9Arefeh Babazadeh10Kermanshah University of Medical SciencesShahid Beheshti University of Medical SciencesBabol University of Medical SciencesBabol University of Medical SciencesBabol University of Medical SciencesBabol University of Medical SciencesMayo ClinicUniversity of NicosiaUniversity of South AustraliaBabol University of Medical SciencesBabol University of Medical SciencesThe emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end the pandemic. At the beginning of the program, vaccinations were initially targeted only at high-risk groups, such as the elderly, those with comorbidities, or healthcare workers. Although most of the mentioned populations have received the two recommended doses, limited resources have left many authorities with an effective vaccine undersupply. Therefore, policies have been implemented to manage the available doses of the vaccines more efficiently. As there is no universally agreed consensus on this topic, we discuss the different recommendations and guidelines regarding the time interval between the two vaccine doses and explain the different scenarios for applying the two doses.http://dx.doi.org/10.1080/21645515.2022.2066425sars-cov-2covid-19vaccinevaccine developmentimmunization |
| spellingShingle | Zeinab Mohseni Afshar Mohammad Barary Rezvan Hosseinzadeh Bardia Karim Soheil Ebrahimpour Kosar Nazary Terence T. Sio Mark J. M. Sullman Kristin Carson-Chahhoud Emaduddin Moudi Arefeh Babazadeh COVID-19 vaccination challenges: A mini-review Human Vaccines & Immunotherapeutics sars-cov-2 covid-19 vaccine vaccine development immunization |
| title | COVID-19 vaccination challenges: A mini-review |
| title_full | COVID-19 vaccination challenges: A mini-review |
| title_fullStr | COVID-19 vaccination challenges: A mini-review |
| title_full_unstemmed | COVID-19 vaccination challenges: A mini-review |
| title_short | COVID-19 vaccination challenges: A mini-review |
| title_sort | covid 19 vaccination challenges a mini review |
| topic | sars-cov-2 covid-19 vaccine vaccine development immunization |
| url | http://dx.doi.org/10.1080/21645515.2022.2066425 |
| work_keys_str_mv | AT zeinabmohseniafshar covid19vaccinationchallengesaminireview AT mohammadbarary covid19vaccinationchallengesaminireview AT rezvanhosseinzadeh covid19vaccinationchallengesaminireview AT bardiakarim covid19vaccinationchallengesaminireview AT soheilebrahimpour covid19vaccinationchallengesaminireview AT kosarnazary covid19vaccinationchallengesaminireview AT terencetsio covid19vaccinationchallengesaminireview AT markjmsullman covid19vaccinationchallengesaminireview AT kristincarsonchahhoud covid19vaccinationchallengesaminireview AT emaduddinmoudi covid19vaccinationchallengesaminireview AT arefehbabazadeh covid19vaccinationchallengesaminireview |